![](https://investorshub.advfn.com/uicon/69437.png?cb=1592321837)
Wednesday, October 01, 2008 9:16:00 AM
On February 19, 2008, the Company announced a restructuring of JWH Holding Company, LLC, the Company's Financing and Homebuilding business. Thirty-six underperforming Jim Walter Homes sales centers have been closed as part of the restructuring. As a result, the Company recorded a restructuring charge of $6.8 million in the first quarter of 2008, in Homebuilding, of which $4.3 million related to impairments of property, plant and equipment, $1.7 million related to severance obligations due to a 25 percent reduction in workforce at Homebuilding and $0.8 million related to lease obligations of closed sales centers. This charge appears as restructuring and impairment charges in the statements of income.
Mortgage-Backed and Asset-Backed Notes and Variable Funding Loan Facilities
At the beginning of the second quarter of 2008, the Company had two variable funding loan facilities ("warehouse facilities") totaling $350.0 million that provided temporary warehouse financing to Walter Mortgage Company ("WMC") for its current purchases of instalment notes and mortgages originated by Homebuilding.
On April 30, 2008, the Company repaid all outstanding borrowings and terminated these facilities using proceeds from the amended 2005 Walter Credit Agreement, as discussed above. With the termination of the warehouse facilities, the Company is no longer reliant on the availability of mortgage warehouse facilities or the mortgage-backed securitization market.
In addition, after May 1, 2008, WMC is no longer providing financing to new customers of Homebuilding. However, substantially all of the backlog of homes with signed contracts and those which were under construction as of May 1, 2008, were or are expected to be completed over the next six months and financed by WMC. The Company will finance these WMC instalment notes receivable with operating cash flows or funds from borrowings under the revolving credit facility. Homebuilding is transitioning to a third-party financing model including the use of government-sponsored loan programs.
Recent HCM News
- HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status • GlobeNewswire Inc. • 07/04/2024 12:00:00 AM
- HUTCHMED to Announce 2024 Half-Year Financial Results • GlobeNewswire Inc. • 06/26/2024 08:30:00 AM
- Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024 • GlobeNewswire Inc. • 06/24/2024 09:30:00 AM
- HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda • GlobeNewswire Inc. • 06/21/2024 08:00:00 PM
- HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology • GlobeNewswire Inc. • 06/17/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/07/2024 10:25:35 AM
- HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China • GlobeNewswire Inc. • 06/07/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/03/2024 10:13:17 AM
- HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine • GlobeNewswire Inc. • 06/03/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/31/2024 10:12:22 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/24/2024 10:06:58 AM
- HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 05/24/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/17/2024 02:02:55 PM
- HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees • GlobeNewswire Inc. • 05/17/2024 02:00:00 PM
- HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress • GlobeNewswire Inc. • 05/17/2024 12:00:00 AM
- HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui • GlobeNewswire Inc. • 05/14/2024 12:00:00 AM
- HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China • GlobeNewswire Inc. • 05/14/2024 12:00:00 AM
- HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee • GlobeNewswire Inc. • 05/08/2024 08:30:00 AM
- HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda • GlobeNewswire Inc. • 04/26/2024 12:30:00 PM
- HUTCHMED Highlights Data to be Presented at AACR Congress 2024 • GlobeNewswire Inc. • 04/05/2024 08:30:00 AM
- HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status • GlobeNewswire Inc. • 04/02/2024 04:30:00 AM
- HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC • GlobeNewswire Inc. • 03/28/2024 12:00:00 AM
- HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China • GlobeNewswire Inc. • 03/22/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2024 11:04:49 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/28/2024 11:47:15 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM